DAWN CURTIS: Open Payments
NPI 1124074935 · CLEARWATER, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$369 in 15 payments from 11 companies in 2025. Trend: 2023 $1,337 · 2024 $958 · 2025 $369
Food & beverage: $369
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. | 4 | $103 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| ABBVIE INC. | 1 | $35 |
| Alkermes, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: KYPHON EXPRESS II KYPHOPAK TRAY, INGREZZA, TRINTELLIX, VRAYLAR, ARISTADA, CAPLYTA, COBENFY, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
